AnGes, MedGel to Explore Feasibility of New Anti-Inflammatory Agent

AnGes MG announced on June 8 that, in collaboration with MedGel, it has launched a feasibility study for seeking new applications of NF-kappa B decoy oligo, a kind of nucleic acid medicine. By combining NFkB decoy oligo with a drug delivery material developed by MedGel, the two companies will aim to develop innovative drugs targeting inflammatory diseases. Founded in April 2003, MedGel has expertise in developing base materials for various drugs including protein and nucleic acid medicines.

()a href="http://www.pharmalive.com/News/index.cfm?articleid=246686&categoryid=15" target="_blank">PharmaLive